Benjorna: Phase III data

The double-blind, U.S. Phase III HLD-200-108 trial in 161 patients ages 6-12 with ADHD in a naturalistic setting showed that once-daily oral

Read the full 224 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE